Evidence map›Paper›PMID 37358666›Full record

ArticleJournal of cancer research and clinical oncology2023

Screening and validating circular RNAs that estimate disease risk and treatment response of pediatric acute myeloid leukemia: a microarray-based analyses and RT-qPCR validation.

Fanghua Ye, Chenying Fan, Min Peng, Siqin Liu, Jiajia Dong, Liangchun Yang, Hui Zhang

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Fanghua YeDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Chenying FanDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Min PengDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Siqin LiuDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Jiajia DongDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Liangchun YangDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China.
Hui ZhangDepartment of Pediatrics, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Changsha, 410008, China. langzhang7094@163.com.
Central South University · CNXiangya Hospital Central South University · CN

Funding

National Natural Science Foundation of China No.82000137Natural Science Foundation of Hunan Province of China 2020JJ4918
6 · The paper itself

Abstract

purposeCircular RNA (circRNA) is a type of novel non-coding RNA with close involvement in the tumorigenesis and treatment response of leukemias. This study aimed to screen and validate candidate circRNAs that estimate disease risk and response to induction therapy of pediatric acute myeloid leukemia (AML).

methodsBone marrow samples were obtained from 4 complete response (CR) pediatric AML patients, 4 non-CR pediatric AML patients, and 4 controls to screen differentially expressed circRNAs (DECs) through microarray analyses. Ten candidate circRNAs were selected and validated in 40 pediatric AML patients and 10 controls through reverse transcription-quantitative polymerase chain reaction.

resultsMicroarray assay discovered 378 upregulated DECs and 688 downregulated DECs in pediatric AML patients vs. controls; 832 upregulated DECs and 950 downregulated DECs in CR AML patients vs. non-CR AML patients. Then cross-analysis identified 441 DECs that both related to pediatric AML risk and CR achievement. Further validation of ten candidate circRNAs in larger sample-sized populations showed that circ_0032891, circ_0076995, circ_0014352, circ_0047663, circ_0007444, circ_0001684, circ_0000544, and circ_0005354 were related to pediatric AML risk; circ_0032891, circ_0076995, circ_0014352, circ_0047663, circ_0007444, circ_0001684, and circ_0000544 were related to CR achievement in pediatric AML patients. Regarding the correlation of candidate circRNAs with survival profile, only circ_0032891, circ_0076995, and circ_0000544 forecasted event-free survival; circ_0076995 and circ_0001684 estimated overall survival in pediatric AML patients.

conclusionCircRNA profile is intensively implicated in the disease risk and treatment response of pediatric AML, especially that circ_0032891, circ_0000544, circ_0076995, and circ_0001684 are related to pediatric AML risk, CR achievement, and survival.

Indexed as

Leukemia, Myeloid, AcuteMicroRNAsChildHumansMicroarray AnalysisRemission InductionRNA, CircularMicroRNAsRNA, CircularCircular RNA profileMicroarrayPediatric acute myeloid leukemiaRT-qPCR validationTreatment response

Identifiers

PMID37358666
PMCPMC11798309
OpenAlexW4382010539

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.